valproic acid has been researched along with Auricular Fibrillation in 6 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A structural, electrical and metabolic atrial remodeling is central in the development of atrial fibrillation (AF) contributing to its initiation and perpetuation." | 5.51 | HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice. ( Hamer, S; Hammer, E; Himmler, K; Müller, FU; Pluteanu, F; Scholz, B; Schulte, JS; Seidl, MD; Stein, J; Völker, U; Wardelmann, E, 2019) |
| "Valproic acid (VPA) and warfarin are commonly prescribed for patients with epilepsy and concomitant atrial fibrillation (AF)." | 4.98 | The critical interaction between valproate sodium and warfarin: case report and review. ( Dong, C; Ren, L; Song, P; Sui, Y; Sun, X; Xu, B; Zhao, W; Zhou, C, 2018) |
| "This study revealed the higher risk of cardiac arrhythmias persists long term in people with epilepsy, especially among those using carbamazepine and valproic acid." | 4.31 | Epilepsy and long-term risk of arrhythmias. ( Cai, J; Feng, Z; Huang, P; Liu, P; Lu, J; Lu, Y; Tang, H; Wang, J; Yang, G; Yang, Y; Yu, Q; Yuan, H, 2023) |
| "A structural, electrical and metabolic atrial remodeling is central in the development of atrial fibrillation (AF) contributing to its initiation and perpetuation." | 1.51 | HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice. ( Hamer, S; Hammer, E; Himmler, K; Müller, FU; Pluteanu, F; Scholz, B; Schulte, JS; Seidl, MD; Stein, J; Völker, U; Wardelmann, E, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Huang, P | 1 |
| Yu, Q | 1 |
| Lu, J | 1 |
| Liu, P | 1 |
| Yang, Y | 1 |
| Feng, Z | 1 |
| Cai, J | 1 |
| Yang, G | 1 |
| Yuan, H | 1 |
| Tang, H | 1 |
| Lu, Y | 1 |
| Langenbruch, L | 1 |
| Meuth, SG | 1 |
| Wiendl, H | 1 |
| Mesters, R | 1 |
| Möddel, G | 1 |
| Zhou, C | 1 |
| Sui, Y | 1 |
| Zhao, W | 1 |
| Dong, C | 1 |
| Ren, L | 1 |
| Song, P | 1 |
| Xu, B | 1 |
| Sun, X | 1 |
| Scholz, B | 1 |
| Schulte, JS | 1 |
| Hamer, S | 1 |
| Himmler, K | 1 |
| Pluteanu, F | 1 |
| Seidl, MD | 1 |
| Stein, J | 1 |
| Wardelmann, E | 1 |
| Hammer, E | 1 |
| Völker, U | 1 |
| Müller, FU | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Vedovello, M | 1 |
| Baldacci, F | 1 |
| Nuti, A | 1 |
| Cipriani, G | 1 |
| Ulivi, M | 1 |
| Vergallo, A | 1 |
| Borelli, P | 1 |
1 review available for valproic acid and Auricular Fibrillation
| Article | Year |
|---|---|
The critical interaction between valproate sodium and warfarin: case report and review.
Topics: Aged; Anticoagulants; Anticonvulsants; Atrial Fibrillation; Drug Interactions; Female; Humans; Inter | 2018 |
5 other studies available for valproic acid and Auricular Fibrillation
| Article | Year |
|---|---|
Epilepsy and long-term risk of arrhythmias.
Topics: Atrial Fibrillation; Carbamazepine; Epilepsy; Genetic Predisposition to Disease; Humans; Valproic Ac | 2023 |
Clinically relevant interaction of rivaroxaban and valproic acid - A case report.
Topics: Administration, Oral; Adult; Anticoagulants; Anticonvulsants; Atrial Fibrillation; Factor Xa Inhibit | 2020 |
HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Remodeling; Cyclic A | 2019 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Peri-ictal prolonged atrial fibrillation after generalized seizures: description of a case and etiopathological considerations.
Topics: Anticonvulsants; Atrial Fibrillation; Electrocardiography; Electroencephalography; Follow-Up Studies | 2012 |